{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T04:19:16Z","timestamp":1784089156605,"version":"3.55.0"},"reference-count":71,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T00:00:00Z","timestamp":1766966400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T00:00:00Z","timestamp":1766966400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP20K17094"],"award-info":[{"award-number":["JP20K17094"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Bayer Research Grant"},{"name":"Research Grant for young medical doctors and healthcare professionals from SRL, Inc."},{"DOI":"10.13039\/100007449","name":"Takeda Science Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007449","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Educator project in Kitasato University Graduate School of Medical Sciences"},{"name":"Kitasato University School of Medicine Keyaki Kai Research Grant"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-29126-8","type":"journal-article","created":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T17:16:46Z","timestamp":1767028606000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Canagliflozin restores electrical properties and suppresses structural damage in isoproterenol-induced myocardial injury models"],"prefix":"10.1038","volume":"15","author":[{"given":"Lisa","family":"Kitasato","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Murayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naruya","family":"Ishizue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuhei","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Oikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidehira","family":"Fukaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinichi","family":"Niwano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junya","family":"Ako","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,29]]},"reference":[{"key":"29126_CR1","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1124\/jpet.116.232025","volume":"358","author":"R Ohgaki","year":"2016","unstructured":"Ohgaki, R. et al. Interaction of the Sodium\/Glucose cotransporter (SGLT) 2 inhibitor Canagliflozin with SGLT1 and SGLT2. J. Pharmacol. Exp. Ther. 358, 94\u2013102. https:\/\/doi.org\/10.1124\/jpet.116.232025 (2016).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"29126_CR2","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1161\/CIRCULATIONAHA.117.032038","volume":"137","author":"KW Mahaffey","year":"2018","unstructured":"Mahaffey, K. W. et al. Canagliflozin for primary and secondary prevention of cardiovascular events: results from the CANVAS program (Canagliflozin cardiovascular assessment Study). Circulation 137, 323\u2013334. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.117.032038 (2018).","journal-title":"Circulation"},{"key":"29126_CR3","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1038\/s41591-022-01703-8","volume":"28","author":"JA Spertus","year":"2022","unstructured":"Spertus, J. A. et al. The SGLT2 inhibitor Canagliflozin in heart failure: the CHIEF-HF remote, patient-centered randomized trial. Nat. Med. 28, 809\u2013813. https:\/\/doi.org\/10.1038\/s41591-022-01703-8 (2022).","journal-title":"Nat. Med."},{"key":"29126_CR4","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.jacbts.2018.10.002","volume":"4","author":"VG Lim","year":"2019","unstructured":"Lim, V. G. et al. SGLT2 Inhibitor, Canagliflozin, attenuates myocardial infarction in the diabetic and nondiabetic heart. JACC Basic. Transl Sci. 4, 15\u201326. https:\/\/doi.org\/10.1016\/j.jacbts.2018.10.002 (2019).","journal-title":"JACC Basic. Transl Sci."},{"key":"29126_CR5","doi-asserted-by":"publisher","first-page":"2099","DOI":"10.1056\/NEJMc1712572","volume":"377","author":"B Neal","year":"2017","unstructured":"Neal, B., Perkovic, V. & Matthews, D. R. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl. J. Med. 377, 2099. https:\/\/doi.org\/10.1056\/NEJMc1712572 (2017).","journal-title":"N Engl. J. Med."},{"key":"29126_CR6","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/s12933-018-0717-9","volume":"17","author":"D Matsutani","year":"2018","unstructured":"Matsutani, D. et al. Effect of Canagliflozin on left ventricular diastolic function in patients with type 2 diabetes. Cardiovasc. Diabetol. 17, 73. https:\/\/doi.org\/10.1186\/s12933-018-0717-9 (2018).","journal-title":"Cardiovasc. Diabetol."},{"key":"29126_CR7","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1093\/cvr\/26.8.740","volume":"26","author":"MP Pye","year":"1992","unstructured":"Pye, M. P. & Cobbe, S. M. Mechanisms of ventricular arrhythmias in cardiac failure and hypertrophy. Cardiovasc. Res. 26, 740\u2013750. https:\/\/doi.org\/10.1093\/cvr\/26.8.740 (1992).","journal-title":"Cardiovasc. Res."},{"key":"29126_CR8","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/j.yjmcc.2010.01.009","volume":"48","author":"Y Wang","year":"2010","unstructured":"Wang, Y. & Hill, J. A. Electrophysiological remodeling in heart failure. J. Mol. Cell. Cardiol. 48, 619\u2013632. https:\/\/doi.org\/10.1016\/j.yjmcc.2010.01.009 (2010).","journal-title":"J. Mol. Cell. Cardiol."},{"key":"29126_CR9","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/s0022-2828(85)80130-9","volume":"17","author":"G Rona","year":"1985","unstructured":"Rona, G. Catecholamine cardiotoxicity. J. Mol. Cell. Cardiol. 17, 291\u2013306. https:\/\/doi.org\/10.1016\/s0022-2828(85)80130-9 (1985).","journal-title":"J. Mol. Cell. Cardiol."},{"key":"29126_CR10","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1093\/eurjhf\/hfn026","volume":"11","author":"P Krenek","year":"2009","unstructured":"Krenek, P. et al. Isoproterenol-induced heart failure in the rat is associated with nitric oxide-dependent functional alterations of cardiac function. Eur. J. Heart Fail. 11, 140\u2013146. https:\/\/doi.org\/10.1093\/eurjhf\/hfn026 (2009).","journal-title":"Eur. J. Heart Fail."},{"key":"29126_CR11","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1536\/ihj.18-226","volume":"60","author":"N Ishizue","year":"2019","unstructured":"Ishizue, N. et al. Linagliptin suppresses electrical and structural remodeling in the isoproterenol induced myocardial injury model. Int. Heart J. 60, 411\u2013418. https:\/\/doi.org\/10.1536\/ihj.18-226 (2019).","journal-title":"Int. Heart J."},{"key":"29126_CR12","doi-asserted-by":"publisher","first-page":"e017483","DOI":"10.1161\/JAHA.119.017483","volume":"10","author":"R Nishinarita","year":"2021","unstructured":"Nishinarita, R. et al. Canagliflozin suppresses atrial remodeling in a canine atrial fibrillation model. J. Am. Heart Assoc. 10, e017483. https:\/\/doi.org\/10.1161\/JAHA.119.017483 (2021).","journal-title":"J. Am. Heart Assoc."},{"key":"29126_CR13","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/s12012-010-9077-8","volume":"10","author":"VR Punithavathi","year":"2010","unstructured":"Punithavathi, V. R., Shanmugapriya, K. & Prince, P. S. Protective effects of Rutin on mitochondrial damage in isoproterenol-induced cardiotoxic rats: an in vivo and in vitro study. Cardiovasc. Toxicol. 10, 181\u2013189. https:\/\/doi.org\/10.1007\/s12012-010-9077-8 (2010).","journal-title":"Cardiovasc. Toxicol."},{"key":"29126_CR14","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1016\/j.bbrc.2004.04.094","volume":"318","author":"B Geng","year":"2004","unstructured":"Geng, B. et al. Endogenous hydrogen sulfide regulation of myocardial injury induced by isoproterenol. Biochem. Biophys. Res. Commun. 318, 756\u2013763. https:\/\/doi.org\/10.1016\/j.bbrc.2004.04.094 (2004).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"29126_CR15","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1177\/0192623307313010","volume":"36","author":"J Zhang","year":"2008","unstructured":"Zhang, J., Knapton, A., Lipshultz, S. E., Weaver, J. L. & Herman, E. H. Isoproterenol-induced cardiotoxicity in sprague-dawley rats: correlation of reversible and irreversible myocardial injury with release of cardiac troponin T and roles of iNOS in myocardial injury. Toxicol. Pathol. 36, 277\u2013278. https:\/\/doi.org\/10.1177\/0192623307313010 (2008).","journal-title":"Toxicol. Pathol."},{"key":"29126_CR16","doi-asserted-by":"publisher","first-page":"2769","DOI":"10.1007\/s12325-019-01045-x","volume":"36","author":"R Nishimura","year":"2019","unstructured":"Nishimura, R. et al. Effect of empagliflozin on free fatty acids and ketone bodies in Japanese patients with type 2 diabetes mellitus: A randomized controlled trial. Adv. Ther. 36, 2769\u20132782. https:\/\/doi.org\/10.1007\/s12325-019-01045-x (2019).","journal-title":"Adv. Ther."},{"key":"29126_CR17","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.diabet.2017.09.006","volume":"44","author":"SH Min","year":"2018","unstructured":"Min, S. H. et al. Degree of ketonaemia and its association with insulin resistance after Dapagliflozin treatment in type 2 diabetes. Diabetes Metab. 44, 73\u201376. https:\/\/doi.org\/10.1016\/j.diabet.2017.09.006 (2018).","journal-title":"Diabetes Metab."},{"key":"29126_CR18","doi-asserted-by":"publisher","unstructured":"Zapata-Sudo, G. et al. Oral treatment with Euterpe oleracea Mart. (acai) extract improves cardiac dysfunction and exercise intolerance in rats subjected to myocardial infarction. BMC Complement. Altern. Med. 14, https:\/\/doi.org\/10.1186\/1472-6882-14-227 (2014).","DOI":"10.1186\/1472-6882-14-227"},{"key":"29126_CR19","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1097\/FJC.0b013e318207a35f","volume":"57","author":"S de Jong","year":"2011","unstructured":"de Jong, S., van Veen, T. A., van Rijen, H. V. & de Bakker, J. M. Fibrosis and cardiac arrhythmias. J. Cardiovasc. Pharmacol. 57, 630\u2013638. https:\/\/doi.org\/10.1097\/FJC.0b013e318207a35f (2011).","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"29126_CR20","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1161\/CIRCRESAHA.115.307778","volume":"118","author":"AR Pinto","year":"2016","unstructured":"Pinto, A. R. et al. Revisiting cardiac cellular composition. Circ. Res. 118, 400\u2013409. https:\/\/doi.org\/10.1161\/CIRCRESAHA.115.307778 (2016).","journal-title":"Circ. Res."},{"key":"29126_CR21","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/s00395-009-0004-8","volume":"104","author":"CP Baines","year":"2009","unstructured":"Baines, C. P. The mitochondrial permeability transition pore and ischemia-reperfusion injury. Basic. Res. Cardiol. 104, 181\u2013188. https:\/\/doi.org\/10.1007\/s00395-009-0004-8 (2009).","journal-title":"Basic. Res. Cardiol."},{"key":"29126_CR22","doi-asserted-by":"publisher","first-page":"1818","DOI":"10.2174\/138161211796390976","volume":"17","author":"T Aoyagi","year":"2011","unstructured":"Aoyagi, T. & Matsui, T. Phosphoinositide-3 kinase signaling in cardiac hypertrophy and heart failure. Curr. Pharm. Des. 17, 1818\u20131824. https:\/\/doi.org\/10.2174\/138161211796390976 (2011).","journal-title":"Curr. Pharm. Des."},{"key":"29126_CR23","doi-asserted-by":"publisher","first-page":"865","DOI":"10.15252\/emmm.201404575","volume":"7","author":"GW Dorn","year":"2015","unstructured":"Dorn, G. W. 2 Mitochondrial dynamism and heart disease: changing shape and shaping change. EMBO Mol. Med. 7, 865\u2013877. https:\/\/doi.org\/10.15252\/emmm.201404575 (2015).","journal-title":"EMBO Mol. Med."},{"key":"29126_CR24","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1161\/01.res.56.6.884","volume":"56","author":"P Simpson","year":"1985","unstructured":"Simpson, P. Stimulation of hypertrophy of cultured neonatal rat heart cells through an alpha 1-adrenergic receptor and induction of beating through an alpha 1- and beta 1-adrenergic receptor interaction. Evidence for independent regulation of growth and beating. Circ. Res. 56, 884\u2013894. https:\/\/doi.org\/10.1161\/01.res.56.6.884 (1985).","journal-title":"Circ. Res."},{"key":"29126_CR25","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1007\/s00424-023-02848-2","volume":"475","author":"O Lookin","year":"2023","unstructured":"Lookin, O., Boulali, N., Cazorla, O. & de Tombe, P. Impact of stretch on sarcomere length variability in isolated fully relaxed rat cardiac myocytes. Pflugers Arch. 475, 1203\u20131210. https:\/\/doi.org\/10.1007\/s00424-023-02848-2 (2023).","journal-title":"Pflugers Arch."},{"key":"29126_CR26","doi-asserted-by":"publisher","first-page":"10551","DOI":"10.1016\/S0021-9258(19)50052-7","volume":"267","author":"J Sadoshima","year":"1992","unstructured":"Sadoshima, J., Jahn, L., Takahashi, T., Kulik, T. J. & Izumo, S. Molecular characterization of the stretch-induced adaptation of cultured cardiac cells. An in vitro model of load-induced cardiac hypertrophy. J. Biol. Chem. 267, 10551\u201310560 (1992).","journal-title":"J. Biol. Chem."},{"key":"29126_CR27","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1038\/s41580-018-0052-8","volume":"19","author":"C Giorgi","year":"2018","unstructured":"Giorgi, C., Marchi, S. & Pinton, P. The machineries, regulation and cellular functions of mitochondrial calcium. Nat. Rev. Mol. Cell. Biol. 19, 713\u2013730. https:\/\/doi.org\/10.1038\/s41580-018-0052-8 (2018).","journal-title":"Nat. Rev. Mol. Cell. Biol."},{"key":"29126_CR28","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1016\/j.yjmcc.2008.12.011","volume":"46","author":"B O\u2019Rourke","year":"2009","unstructured":"O\u2019Rourke, B. & Blatter, L. A. Mitochondrial Ca2\u2009+\u2009uptake: tortoise or hare? J. Mol. Cell. Cardiol. 46, 767\u2013774. https:\/\/doi.org\/10.1016\/j.yjmcc.2008.12.011 (2009).","journal-title":"J. Mol. Cell. Cardiol."},{"key":"29126_CR29","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.ijcard.2017.05.032","volume":"243","author":"A Di Franco","year":"2017","unstructured":"Di Franco, A. et al. Sodium-dependent glucose transporters (SGLT) in human ischemic heart: A new potential Pharmacological target. Int. J. Cardiol. 243, 86\u201390. https:\/\/doi.org\/10.1016\/j.ijcard.2017.05.032 (2017).","journal-title":"Int. J. Cardiol."},{"key":"29126_CR30","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1186\/s12933-020-01141-1","volume":"19","author":"AA Sayour","year":"2020","unstructured":"Sayour, A. A. et al. Characterization of left ventricular myocardial sodium-glucose cotransporter 1 expression in patients with end-stage heart failure. Cardiovasc. Diabetol. 19, 159. https:\/\/doi.org\/10.1186\/s12933-020-01141-1 (2020).","journal-title":"Cardiovasc. Diabetol."},{"key":"29126_CR31","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/cvr\/cvp190","volume":"84","author":"SK Banerjee","year":"2009","unstructured":"Banerjee, S. K., McGaffin, K. R., Pastor-Soler, N. M. & Ahmad, F. SGLT1 is a novel cardiac glucose transporter that is perturbed in disease States. Cardiovasc. Res. 84, 111\u2013118. https:\/\/doi.org\/10.1093\/cvr\/cvp190 (2009).","journal-title":"Cardiovasc. Res."},{"key":"29126_CR32","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1002\/jcb.10631","volume":"90","author":"L Zhou","year":"2003","unstructured":"Zhou, L. et al. Human cardiomyocytes express high level of Na+\/glucose cotransporter 1 (SGLT1). J. Cell. Biochem. 90, 339\u2013346. https:\/\/doi.org\/10.1002\/jcb.10631 (2003).","journal-title":"J. Cell. Biochem."},{"key":"29126_CR33","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1111\/j.1749-6632.2002.tb04775.x","volume":"976","author":"SM Pogwizd","year":"2002","unstructured":"Pogwizd, S. M. & Bers, D. M. Na\/Ca exchange in heart failure: contractile dysfunction and arrhythmogenesis. Ann. N Y Acad. Sci. 976, 454\u2013465. https:\/\/doi.org\/10.1111\/j.1749-6632.2002.tb04775.x (2002).","journal-title":"Ann. N Y Acad. Sci."},{"key":"29126_CR34","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1007\/BF01149958","volume":"13","author":"EG Krebs","year":"1993","unstructured":"Krebs, E. G. Nobel Lecture. Protein phosphorylation and cellular regulation I. Biosci. Rep. 13, 127\u2013142. https:\/\/doi.org\/10.1007\/BF01149958 (1993).","journal-title":"Biosci. Rep."},{"key":"29126_CR35","doi-asserted-by":"publisher","first-page":"H961","DOI":"10.1152\/ajpheart.1998.275.3.H961","volume":"275","author":"Y Shizukuda","year":"1998","unstructured":"Shizukuda, Y. et al. beta-adrenergic stimulation causes cardiocyte apoptosis: influence of tachycardia and hypertrophy. Am. J. Physiol. 275, H961\u2013968. https:\/\/doi.org\/10.1152\/ajpheart.1998.275.3.H961 (1998).","journal-title":"Am. J. Physiol."},{"key":"29126_CR36","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.yjmcc.2004.11.005","volume":"38","author":"T Matsui","year":"2005","unstructured":"Matsui, T. & Rosenzweig, A. Convergent signal transduction pathways controlling cardiomyocyte survival and function: the role of PI 3-kinase and Akt. J. Mol. Cell. Cardiol. 38, 63\u201371. https:\/\/doi.org\/10.1016\/j.yjmcc.2004.11.005 (2005).","journal-title":"J. Mol. Cell. Cardiol."},{"key":"29126_CR37","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.bcp.2015.10.004","volume":"98","author":"SS Mohamed","year":"2015","unstructured":"Mohamed, S. S., Ahmed, L. A., Attia, W. A. & Khattab, M. M. Nicorandil enhances the efficacy of mesenchymal stem cell therapy in isoproterenol-induced heart failure in rats. Biochem. Pharmacol. 98, 403\u2013411. https:\/\/doi.org\/10.1016\/j.bcp.2015.10.004 (2015).","journal-title":"Biochem. Pharmacol."},{"key":"29126_CR38","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1161\/01.res.87.12.1172","volume":"87","author":"A Chesley","year":"2000","unstructured":"Chesley, A. et al. The beta(2)-adrenergic receptor delivers an antiapoptotic signal to cardiac myocytes through G(i)-dependent coupling to phosphatidylinositol 3\u2019-kinase. Circ. Res. 87, 1172\u20131179. https:\/\/doi.org\/10.1161\/01.res.87.12.1172 (2000).","journal-title":"Circ. Res."},{"key":"29126_CR39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s12276-019-0355-7","volume":"51","author":"JN Peoples","year":"2019","unstructured":"Peoples, J. N., Saraf, A., Ghazal, N., Pham, T. T. & Kwong, J. Q. Mitochondrial dysfunction and oxidative stress in heart disease. Exp. Mol. Med. 51, 1\u201313. https:\/\/doi.org\/10.1038\/s12276-019-0355-7 (2019).","journal-title":"Exp. Mol. Med."},{"key":"29126_CR40","doi-asserted-by":"publisher","first-page":"14459","DOI":"10.1038\/s41598-020-71449-1","volume":"10","author":"R Hasan","year":"2020","unstructured":"Hasan, R. et al. Canagliflozin attenuates isoprenaline-induced cardiac oxidative stress by stimulating multiple antioxidant and anti-inflammatory signaling pathways. Sci. Rep. 10, 14459. https:\/\/doi.org\/10.1038\/s41598-020-71449-1 (2020).","journal-title":"Sci. Rep."},{"key":"29126_CR41","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1111\/dom.12881","volume":"19","author":"A Jobori","year":"2017","unstructured":"Jobori, A. Determinants of the increase in ketone concentration during SGLT2 Inhibition in NGT, IFG and T2DM patients. Diabetes Obes. Metab. 19, 809\u2013813. https:\/\/doi.org\/10.1111\/dom.12881 (2017).","journal-title":"Diabetes Obes. Metab."},{"key":"29126_CR42","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.2337\/db15-1356","volume":"65","author":"E Ferrannini","year":"2016","unstructured":"Ferrannini, E. et al. Shift to fatty substrate utilization in response to Sodium-Glucose cotransporter 2 Inhibition in subjects without diabetes and patients with type 2 diabetes. Diabetes 65, 1190\u20131195. https:\/\/doi.org\/10.2337\/db15-1356 (2016).","journal-title":"Diabetes"},{"issue":"6116","key":"29126_CR43","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1126\/science.1227166","volume":"339","author":"T Shimazu","year":"2013","unstructured":"Shimazu, T. et al. Suppression of oxidative stress by \u03b2-hydroxybutyrate, an endogenous histone deacetylase inhibitor. Science 339 (6116), 211\u2013214. https:\/\/doi.org\/10.1126\/science.1227166 (2013).","journal-title":"Science"},{"key":"29126_CR44","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1111\/jcmm.13394","volume":"22","author":"X Rossello","year":"2018","unstructured":"Rossello, X., Riquelme, J. A., Davidson, S. M. & Yellon, D. M. Role of PI3K in myocardial ischaemic preconditioning: mapping pro-survival cascades at the trigger phase and at reperfusion. J. Cell. Mol. Med. 22, 926\u2013935. https:\/\/doi.org\/10.1111\/jcmm.13394 (2018).","journal-title":"J. Cell. Mol. Med."},{"key":"29126_CR45","doi-asserted-by":"publisher","first-page":"3842","DOI":"10.7150\/thno.19764","volume":"7","author":"Y Zeng","year":"2017","unstructured":"Zeng, Y. et al. A circular RNA binds to and activates AKT phosphorylation and nuclear localization reducing apoptosis and enhancing cardiac repair. Theranostics 7, 3842\u20133855. https:\/\/doi.org\/10.7150\/thno.19764 (2017).","journal-title":"Theranostics"},{"key":"29126_CR46","doi-asserted-by":"publisher","unstructured":"Huang, Q. et al. Canagliflozin attenuates post-resuscitation myocardial dysfunction in diabetic rats by inhibiting autophagy through the PI3K\/Akt\/mTOR pathway. iScience 27, 110429, (2024). https:\/\/doi.org\/10.1016\/j.isci.2024.110429","DOI":"10.1016\/j.isci.2024.110429"},{"key":"29126_CR47","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1186\/s12933-024-02481-y","volume":"23","author":"FR Alsereidi","year":"2024","unstructured":"Alsereidi, F. R. et al. Dapagliflozin mitigates cellular stress and inflammation through PI3K\/AKT pathway modulation in cardiomyocytes, aortic endothelial cells, and stem cell-derived beta cells. Cardiovasc. Diabetol. 23, 388. https:\/\/doi.org\/10.1186\/s12933-024-02481-y (2024).","journal-title":"Cardiovasc. Diabetol."},{"key":"29126_CR48","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1146\/annurev.physiol.65.092101.142243","volume":"65","author":"N Frey","year":"2003","unstructured":"Frey, N. & Olson, E. N. Cardiac hypertrophy: the good, the bad, and the ugly. Annu. Rev. Physiol. 65, 45\u201379. https:\/\/doi.org\/10.1146\/annurev.physiol.65.092101.142243 (2003).","journal-title":"Annu. Rev. Physiol."},{"key":"29126_CR49","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1093\/cvr\/cvn243","volume":"81","author":"GW Dorn","year":"2009","unstructured":"Dorn, G. W. 2 Apoptotic and non-apoptotic programmed cardiomyocyte death in ventricular remodelling. Cardiovasc. Res. 81, 465\u2013473. https:\/\/doi.org\/10.1093\/cvr\/cvn243 (2009).","journal-title":"Cardiovasc. Res."},{"key":"29126_CR50","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/s41569-018-0007-y","volume":"15","author":"M Nakamura","year":"2018","unstructured":"Nakamura, M. & Sadoshima, J. Mechanisms of physiological and pathological cardiac hypertrophy. Nat. Rev. Cardiol. 15, 387\u2013407. https:\/\/doi.org\/10.1038\/s41569-018-0007-y (2018).","journal-title":"Nat. Rev. Cardiol."},{"key":"29126_CR51","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1002\/j.1460-2075.1993.tb05813.x","volume":"12","author":"J Sadoshima","year":"1993","unstructured":"Sadoshima, J. & Izumo, S. Mechanical stretch rapidly activates multiple signal transduction pathways in cardiac myocytes: potential involvement of an autocrine\/paracrine mechanism. EMBO J. 12, 1681\u20131692. https:\/\/doi.org\/10.1002\/j.1460-2075.1993.tb05813.x (1993).","journal-title":"EMBO J."},{"key":"29126_CR52","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s12576-008-0006-6","volume":"59","author":"J Shimizu","year":"2009","unstructured":"Shimizu, J. et al. Increased O2 consumption in excitation-contraction coupling in hypertrophied rat heart slices related to increased Na+ -Ca2\u2009+\u2009exchange activity. J. Physiol. Sci. 59, 63\u201374. https:\/\/doi.org\/10.1007\/s12576-008-0006-6 (2009).","journal-title":"J. Physiol. Sci."},{"key":"29126_CR53","doi-asserted-by":"publisher","first-page":"H2154","DOI":"10.1152\/ajpheart.00483.2011","volume":"301","author":"M Shibata","year":"2011","unstructured":"Shibata, M. et al. NHE-1 participates in isoproterenol-induced downregulation of SERCA2a and development of cardiac remodeling in rat hearts. Am. J. Physiol. Heart Circ. Physiol. 301, H2154\u20132160. https:\/\/doi.org\/10.1152\/ajpheart.00483.2011 (2011).","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"29126_CR54","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1016\/j.yjmcc.2010.06.003","volume":"49","author":"SK Banerjee","year":"2010","unstructured":"Banerjee, S. K. et al. SGLT1, a novel cardiac glucose transporter, mediates increased glucose uptake in PRKAG2 cardiomyopathy. J. Mol. Cell. Cardiol. 49, 683\u2013692. https:\/\/doi.org\/10.1016\/j.yjmcc.2010.06.003 (2010).","journal-title":"J. Mol. Cell. Cardiol."},{"key":"29126_CR55","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1038\/cr.2010.178","volume":"21","author":"MJ Morgan","year":"2011","unstructured":"Morgan, M. J. & Liu, Z. G. Crosstalk of reactive oxygen species and NF-kappaB signaling. Cell. Res. 21, 103\u2013115. https:\/\/doi.org\/10.1038\/cr.2010.178 (2011).","journal-title":"Cell. Res."},{"key":"29126_CR56","doi-asserted-by":"crossref","unstructured":"Zheng, Z. X. et al. Canagliflozin ameliorates neuronal injury after cerebral ischemia reperfusion by targeting SGLT1 and AMPK-dependent apoptosis. Neurotherapeutics 21, doi:ARTN e0030510.1016\/j.neurot.11.002 (2024). (2023).","DOI":"10.1016\/j.neurot.2023.11.002"},{"key":"29126_CR57","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1007\/s10557-018-6837-3","volume":"32","author":"YM Ye","year":"2018","unstructured":"Ye, Y. M., Jia, X. M., Bajaj, M. & Birnbaum, Y. Dapagliflozin attenuates Na\/H Exchanger-1 in cardiofibroblasts via AMPK activation. Cardiovasc. Drug Ther. 32, 553\u2013558. https:\/\/doi.org\/10.1007\/s10557-018-6837-3 (2018).","journal-title":"Cardiovasc. Drug Ther."},{"key":"29126_CR58","doi-asserted-by":"crossref","unstructured":"Uthman, L. et al. Direct Cardiac Actions of Sodium Glucose Cotransporter 2 Inhibitors Target Pathogenic Mechanisms Underlying Heart Failure in Diabetic Patients. Frontiers in Physiology 9, doi:ARTN 157510.3389\/fphys.01575 (2018). (2018).","DOI":"10.3389\/fphys.2018.01575"},{"key":"29126_CR59","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s12933-019-0980-4","volume":"19","author":"M Arow","year":"2020","unstructured":"Arow, M. et al. Sodium-glucose cotransporter 2 inhibitor Dapagliflozin attenuates diabetic cardiomyopathy. Cardiovasc. Diabetol. 19, 7. https:\/\/doi.org\/10.1186\/s12933-019-0980-4 (2020).","journal-title":"Cardiovasc. Diabetol."},{"issue":"16","key":"29126_CR60","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1161\/CIRCULATIONAHA.122.057364","volume":"146","author":"J Mustroph","year":"2022","unstructured":"Mustroph, J. et al. Empagliflozin inhibits cardiac late sodium current by Ca\/Calmodulin-Dependent kinase II. Circulation 146 (16), 1259\u20131261. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.122.057364 (2022). Epub 2022 Oct 17.","journal-title":"Circulation"},{"key":"29126_CR61","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s12933-019-0828-y","volume":"18","author":"CMA Cefalo","year":"2019","unstructured":"Cefalo, C. M. A. et al. Sotagliflozin, the first dual SGLT inhibitor: current outlook and perspectives. Cardiovasc. Diabetol. 18, 20. https:\/\/doi.org\/10.1186\/s12933-019-0828-y (2019).","journal-title":"Cardiovasc. Diabetol."},{"key":"29126_CR62","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.ejphar.2018.09.019","volume":"838","author":"V Tsimihodimos","year":"2018","unstructured":"Tsimihodimos, V., Filippas-Ntekouan, S. & Elisaf, M. SGLT1 inhibition: pros and cons. Eur. J. Pharmacol. 838, 153\u2013156. https:\/\/doi.org\/10.1016\/j.ejphar.2018.09.019 (2018).","journal-title":"Eur. J. Pharmacol."},{"key":"29126_CR63","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1056\/NEJMoa2030186","volume":"384","author":"DL Bhatt","year":"2021","unstructured":"Bhatt, D. L. et al. Sotagliflozin in patients with diabetes and chronic kidney disease. N Engl. J. Med. 384, 129\u2013139. https:\/\/doi.org\/10.1056\/NEJMoa2030186 (2021).","journal-title":"N Engl. J. Med."},{"key":"29126_CR64","doi-asserted-by":"publisher","first-page":"175720","DOI":"10.1016\/j.ejphar.2023.175720(","volume":"949","author":"D Dasari","year":"2023","unstructured":"Dasari, D., Goyal, S. G., Penmetsa, A., Sriram, D. & Dhar, A. Canagliflozin protects diabetic cardiomyopathy by mitigating fibrosis and preserving the myocardial integrity with improved mitochondrial function. Eur. J. Pharmacol. 949, 175720. https:\/\/doi.org\/10.1016\/j.ejphar.2023.175720 (2023).","journal-title":"Eur. J. Pharmacol."},{"key":"29126_CR65","doi-asserted-by":"publisher","unstructured":"Nasiri-Ansari, \u039d. et al. Canagliflozin attenuates the progression of atherosclerosis and inflammation process in APOE knockout mice. Cardiovasc Diabetol. 17(1), 106. (2018). https:\/\/doi.org\/10.1186\/s12933-018-0749-1","DOI":"10.1186\/s12933-018-0749-1"},{"key":"29126_CR66","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1038\/s42003-023-05289-w","volume":"6","author":"A Ali","year":"2023","unstructured":"Ali, A. et al. The SGLT2 inhibitor Canagliflozin suppresses growth and enhances prostate cancer response to radiotherapy. Commun. Biol. 6, 919 (2023).","journal-title":"Commun. Biol."},{"key":"29126_CR67","doi-asserted-by":"publisher","first-page":"27","DOI":"10.4103\/0976-0105.177703","volume":"7","author":"AB Nair","year":"2016","unstructured":"Nair, A. B. & Jacob, S. A simple practice guide for dose conversion between animals and human. J. Basic. Clin. Pharma. 7, 27\u201331 (2016).","journal-title":"J. Basic. Clin. Pharma"},{"key":"29126_CR68","doi-asserted-by":"publisher","first-page":"1950","DOI":"10.1253\/circj.cj-13-1587","volume":"78","author":"S Kurokawa","year":"2014","unstructured":"Kurokawa, S. et al. Cardiomyocyte-derived mitochondrial superoxide causes myocardial electrical remodeling by downregulating potassium channels and related molecules. Circ. J. 78, 1950\u20131959. https:\/\/doi.org\/10.1253\/circj.cj-13-1587 (2014).","journal-title":"Circ. J."},{"key":"29126_CR69","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.placenta.2024.07.001","volume":"154","author":"L Kitasato","year":"2024","unstructured":"Kitasato, L. et al. Fibroblasts activation by embryonic signal switching: A novel mechanism of placental growth factor-induced cardiac remodeling. Placenta 154, 129\u2013136. https:\/\/doi.org\/10.1016\/j.placenta.2024.07.001 (2024).","journal-title":"Placenta"},{"key":"29126_CR70","doi-asserted-by":"publisher","unstructured":"Kitasato, L. et al. Rivaroxaban as a protector of Oxidative Stress-induced Vascular Endothelial Glycocalyx Damage via The IQGAP1\/PAR1-2\/PI3K\/Akt Pathway. J. Vasc Res. 1\u201324. https:\/\/doi.org\/10.1159\/000542419 (2024).","DOI":"10.1159\/000542419"},{"issue":"1","key":"29126_CR71","first-page":"003","volume":"2","author":"L Kitasato","year":"2015","unstructured":"Kitasato, L. et al. Endothelial cell survival under high glucose condition: effect of Rivaroxaban. Envliven: Clin. Cardiol. Res. 2 (1), 003 (2015).","journal-title":"Envliven: Clin. Cardiol. Res."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-29126-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-29126-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-29126-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T12:39:05Z","timestamp":1777120745000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-29126-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,29]]},"references-count":71,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["29126"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-29126-8","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,29]]},"assertion":[{"value":"16 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All animal experiments were approved by the Ethics Committee for Animal Experiments of Kitasato University (approval number: 2023\u2009\u2212\u2009120) and conducted in accordance with the institutional guidelines for animal care and use. The authors confirm that all procedures complied with the ARRIVE guidelines.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Approval for animal experiments"}},{"value":"All authors have declared their consent of publication.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent of publication"}}],"article-number":"44958"}}